The company today informed the National Stock Exchange (NSE) that it has received approval for the Abbreviated New Drug Application (ANDA) for Rivastigmine Capsules in 1.5 mg, 3 mg, 4.5 mg and 6 mg and Felodipine extended release tablets in three strengths including 5 mg and 10 mg.
According to information available, Rivastigmine is used for treatment of memory problems associated with Alzheimer's disease and with Parkinson's disease. Swiss pharma major Novartis has its brand Exelon with this ingredient. Felodipine extended release is used to control High blood pressure and has been marketed by AstraZeneca and Sanofi Aventis under the brand names Plendil and Renedil, respectively.